Printer Friendly

CARDIOVASCULAR DIAGNOSTICS ACQUIRES RIGHTS FOR NOVEL IMMUNOASSAY TECHNOLOGY AND WILL DEVELOP TESTS FOR DIAGNOSING HEART ATTACKS

 RESEARCH TRIANGLE PARK, N.C., June 8 /PRNewswire/ -- Cardiovascular Diagnostics, Inc. (CDI) has acquired worldwide manufacturing and distribution rights for a novel medical diagnostic technology from Duke University Department of Chemistry. CDI will use the innovative technology, called Light Activated Acyl-Enzymes (LAAE), to develop fast, accurate, and simple whole blood tests for diagnosing heart attacks and atherosclerosis (hardening of the arteries). One patent has been issued for LAAE and another patent application has been submitted.
 CDI will incorporate LAAE into the same disposable test card format it now uses with its portable analyzer for monitoring patients receiving anticoagulant and thrombolytic drugs. Test results will be available in minutes, and the tests themselves will be convenient, since only a drop of unmeasured, unprocessed whole blood is needed to perform them.
 The tests will aid a physician who is trying to determine whether a person complaining of chest pains is actually suffering from a heart attack. Having tests performed at the point-of-patient care should result in faster and more appropriate treatment for patients.
 CDI will also develop a whole blood test panel using LAAE that will be designed to identify persons with a potential for atherosclerosis, enabling physicians to prescribe preventive treatment.
 The new technology could be applied to therapeutic drug monitoring, drugs of abuse testing, and infectious disease diagnosis, providing greater sensitivity than is currently available.
 -0- 6/8/93
 /CONTACT: Jonathon Lawrie, President, 919-544-2952, or Craig Carpenter, Director of Sales and Marketing, 919-544-2952, both of Cardiovascular Diagnostics/


CO: Cardiovascular Diagnostics, Inc. ST: North Carolina IN: MTC SU: PDT

CM -- CH005 -- 6627 06/08/93 14:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:267
Previous Article:THE SEATTLE TIMES INTRODUCES NEW DESIGN TODAY
Next Article:RPM, INC. COMPLETES ACQUISITION OF DYNATRON/BONDO CORPORATION
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES ISSUED U.S. PATENT NO. 5,453,359 FOR THROMBUS PRECURSOR PROTEIN (TpP) (SOLUBLE FIBRIN POLYMER)
IGEN Acquires Exclusive Rights for a Method to Screen and Monitor Heart Failure Risk
Bio-Rad Laboratories and Axis-Shield Group Sign Exclusive Licensing Agreement.
Lp-PLA2 Targeted for Therapeutic Intervention; diaDexus Offers FDA-Cleared Test to Measure Lp-PLA2.
Biosite Incorporated Triage BNP Test Approved for Usage on Beckman Coulter Platforms.
Agenix and Biosite enter into license for D-dimer.
Bayer Diagnostics Expands Its BNP Assay Offering Worldwide - Now Available on the ACS:180(R) Immunoassay System; Test Ideal for Small Volume...
New England Journal of Medicine Highlights BNP as Early Warning Signal For Future Cardiovascular Disease.
Abbott Laboratories Announces US 510(K) Clearance and International Launch of Archtect(R) Stat Troponin-I Test That Aids in Heart Attack Detection;...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters